Daily Pivots: (S1) 1.2685; (P) 1.2749; (R1) 1.2792; More… Intraday bias in USD/CAD remains neutral and outlook is unchanged. As long as 1.2604 support holds, we’d still slightly favor another rally. Break of 1.2963 will Read more…
Daily Pivots: (S1) 0.7132; (P) 0.7177; (R1) 0.7209; More… Intraday bias in AUD/USD remains neutral for the moment. On the downside, break of 0.7081 support will indicate that corrective rebound from 0.6992 has completed with Read more…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set new standards by using so-called nanoplates Read more…
Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Read more…
Daily Pivots: (S1) 115.60; (P) 115.89; (R1) 116.16; More… Intraday bias in USD/JPY remains neutral for consolidation below 116.34 temporary top. Downside of retreat should be contained well above 114.26 support turned resistance to bring Read more…
Daily Pivots: (S1) 0.9179; (P) 0.9202; (R1) 0.9235; More…. USD/CHF’s break of 0.9200 resistance suggests that fall from 0.9372 has completed with three waves down to 0.9101. Intraday bias is back on the upside for Read more…
Daily Pivots: (S1) 1.3498; (P) 1.3528; (R1) 1.3567; More… Intraday bias in GBP/USD remains neutral and outlook is unchanged. Further rally is still expected as long as 1.3430 support holds. We’re seeing corrective fall from Read more…
Lots of noise, but little substance probably describes the last 24 hours in global markets. US equities moved sideways overnight, the US Dollar was steady versus major currencies, US yields edged a little higher, while Read more…
STMicroelectronics Announces Fourth Quarter 2021 Preliminary Revenues and Timing for its Fourth Quarter and Full Year 2021 Earnings Release and Conference Call Preliminary Q421 net revenues of $3.56 billion, above the outlook range Q4&FY21 earnings Read more…
Regulatory News: argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its strategic priorities for 2022 and highlighted recent achievements from Read more…